Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part, Randomised, Placebo-Controlled, Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Study Of LAS190792 Delivered By Inhalation In Asthmatic And Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT02059434 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02059434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02059434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part, Randomised, Placebo-Controlled, Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Study Of LAS190792 Delivered By Inhalation In Asthmatic And Chronic Obstructive Pulmonary Disease (COPD) Subjects
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2013
Completion date
October 6, 2014
Enrollment
55 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, chronic obstructive pulmonary disease (copd)